Gyre Therapeutics Gets Regulatory Priority Review for Liver Fibrosis Treatment in China
MT Newswires Live
Jan 05
Gyre Therapeutics (GYRE) said Monday its Chinese unit reached an agreement with China's Center for Drug Evaluation to seek conditional approval for its liver fibrosis treatment Hydronidone.
The CDE determined that current phase 3 clinical data support the submission of an application for chronic hepatitis B-associated liver fibrosis, the company said.
The company also said it intends to file the formal marketing application during H1 of 2026.
It will also perform a confirmatory clinical study to track long-term health outcomes and support a transition to full regulatory approval, Gyre said.
Shares of the company were up by over 2% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.